Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango

Bibliography

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17
   PubMed Web of Science ®Google Scholar
• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356(6364):63-6
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005;11(6):626-34
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-81
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-74
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-33
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18(2):143-52
   PubMed Web of Science ®Google Scholar
• Bloomgren G. Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68(3):295-303
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 2000;59(3):401-10
   PubMed Web of Science ®Google Scholar
• Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord 2010;3(5):293-9
   PubMedGoogle Scholar
• Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994;94(5):1722-8
   PubMed Web of Science ®Google Scholar
• Tubridy N, Behan PO, Capildeo R, et al. The UK Antegren Study Group. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999;3(3):466-72
   Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009;72(9):806-12
   PubMed Web of Science ®Google Scholar
• Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006;60(2):162-73
   PubMed Web of Science ®Google Scholar
• Bickston SJ, Muniyappa K. Natalizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol 2010;6(4):513-19
   PubMed Web of Science ®Google Scholar
• Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest 2008;118(3):825-6
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-8
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368(17):1658-9
   PubMed Web of Science ®Google Scholar
• Kuehn BM. FDA notes rare infection in patient who took fingolimod for ms. JAMA 2013;310(16):1666-6
   Web of Science ®Google Scholar
• Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71(1):115-23
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59(5):743-7
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4):438-46
   PubMed Web of Science ®Google Scholar
• Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72(5):779-87
   PubMed Web of Science ®Google Scholar
• Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012;123(2):235-45
   PubMed Web of Science ®Google Scholar
• Schroder A, Lee DH, Hellwig K, et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010;67(11):1391-4
   PubMed Web of Science ®Google Scholar
• Linda H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 2013;4:11
   PubMed Web of Science ®Google Scholar
• Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013;84(10):1068-74
   PubMed Web of Science ®Google Scholar
• Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med 2011;78(Suppl 2):S33-7
   PubMedGoogle Scholar
• Baldwin KJ, Hogg JP. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013;26(3):318-23
   PubMed Web of Science ®Google Scholar
• Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012;78(6):436-7
   PubMed Web of Science ®Google Scholar
• Rudick RA, O'Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010;68(3):304-10
   PubMed Web of Science ®Google Scholar
• Abstracts from the 25th Annual Meeting of the Consortium of Multiple Sclerosis Centers. Int J MS Care 2011. 13(S3):1-96
   Google Scholar
• Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81(10):865-71
   PubMed Web of Science ®Google Scholar
• O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76(22):1858-65
   PubMed Web of Science ®Google Scholar
• Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011;17(3):372-5
   PubMed Web of Science ®Google Scholar
• Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 2011;17(4):490-4
   PubMed Web of Science ®Google Scholar
• Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010;68(3):392-5
   PubMed Web of Science ®Google Scholar
• West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010;68(3):395-9
   PubMed Web of Science ®Google Scholar
• Cree B, De Seze J, Fox R, et al. RESTORE study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity. Neurology 2012; P06.168
   PubMed Web of Science ®Google Scholar
• de Andres C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One 2012;7(4):e34103
   PubMedGoogle Scholar
• Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23(2):133-46
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Rudick RA. Prescribing recommendations for interferon-Beta in multiple sclerosis. CNS Drugs 1997;8(2):102-12
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25
   PubMed Web of Science ®Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-9
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277(24):21453-7
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ramanathan M. Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol 2012;8(2):66-8
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999;52(5):1072-4
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Phillips JT, Goodman AD, et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler 2004;10(5):511-20
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23
   PubMed Web of Science ®Google Scholar
• Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251(4):407-13
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8(3):254-60
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256(3):405-15
   PubMed Web of Science ®Google Scholar
• Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012;19(5):783-7
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15; Expert Opin Pharmacother 2010; 11(10):1777-81
   PubMed Web of Science ®Google Scholar
• Rudick R, Polman C, Clifford D, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol 2013;70:172-82
   PubMed Web of Science ®Google Scholar
• Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012;12:25-35
   PubMedGoogle Scholar